RNA, DNA and custom modified oligonucleotides
Custom RNA, DNA and modified oligonucleotides, with an extensive range of modifications and conjugations.
A full catalogue, built to your
own specification
Whatever the application, we synthesise to your exact specification. The same team that makes your material can also help characterise it, and working through Syngenis Clinical can take it towards the clinic.
Advance your own programs
Synthetic RNA sequences as single or double stranded oligos, with a choice of phosphodiester or phosphorothioate linkage and additional tags at either end (FAM, Biotin or phosphate). Available as phosphodiester (rA, rC, rG, rU) and phosphorothioate (rA*, rC*, rG*, rU*).
Define your own requirements
Custom DNA oligonucleotides synthesised to your specification with phosphodiester or phosphorothioate linkage and the addition of specific tags including FAM, Biotin or phosphate. Available as phosphodiester (dA, dC, dG, dT) and phosphorothioate (dA*, dC*, dG*, dT*).
Specialty chemistries upon request
Modified RNA oligonucleotides with 2' O methyl (2' OMe), 2' O methoxyethyl (2' MOE), 2' fluoro (2' F) or locked nucleic acid (LNA) chemistry, with phosphodiester or phosphorothioate linkage. Includes 2' OMe (mA, mC, mG, mU), 2' MOE (moA, moC, moG, moT), 2' fluoro (fA, fC, fG, fU) and LNA (lA, lC, lG, lT), each available with a phosphorothioate backbone.
Available modifications and conjugations
Linkers and functional groups
- Biotin, Biotin TEG, Amino (C3, C6, C12), Thiol (C3, C6), Alkyne, Azide, DBCO, Cholesterol TEG.
Spacers
- C3, C6, C12, C18, Spacer 9 (TEG), dSpacer (abasic), PC spacer.
Quenchers
- BHQ-1, BHQ-2, BHQ-3, BBQ-650, Dabcyl, Eclipse, MGB.
Fluorophores
- FAM, HEX, TAMRA, Cy3, Cy3.5, Cy5, Cy5.5, ATTO550, AF488, Methylene Blue.
Conjugations
- DOTA, NOTA, NODAGA, GalNAc, PEG, Cholesterol, alpha tocopherol, Digoxigenin.
Custom modifications
- Custom end, internal and dual labelled modifications available on request.
Your R&D programs supported
Our products support therapeutic development (antisense and RNA silencing candidates such as those now approved for rare neurological, cardiometabolic and metabolic disease), diagnostics (probes, primers and aptamers for assays and point of care tests), and research across universities and institutes.
Reap the benefits of an integrated life sciences company
Talk to our team about your program, from candidate design to trial-ready material.